Table 6.
Association of combined Ki-67 and Her2 expression with pT and pN stages in patients with non-metastatic gastric cancer estimated using univariable and multivariable-adjusted logistic regression
| Ki-67 and Her2 expression | Association with pT | Association with pN | ||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Univariable testa | ||||
| Her2 negative and Ki-67 negative | 1 (reference) | 1 (reference) | ||
| Her2 negative and Ki-67 positive | 0.22 (0.06–0.76) | 0.035 | 0.84 (0.45–1.58) | 0.819 |
| Her2 positive and Ki-67 negative | 0.14 (0.03–0.59) | 0.012 | 0.62 (0.24–1.57) | 0.404 |
| Her2 positive and Ki-67 positive | 0.13 (0.03–0.51) | 0.009 | 0.81 (0.37–1.78) | 0.985 |
| Multivariable test 1b | Model 1 | Model 2 | ||
| Her2 negative and Ki-67 negative | 1 (reference) | 1 (reference) | ||
| Her2 negative and Ki-67 positive | 0.14 (0.03–0.61) | 0.044 | 1.08 (0.56–2.08) | 0.673 |
| Her2 positive and Ki-67 negative | 0.11 (0.02–0.64) | 0.029 | 1.21 (0.44–3.34) | 0.942 |
| Her2 positive and Ki-67 positive | 0.07 (0.01–0.39) | 0.025 | 1.48 (0.62–3.55) | 0.429 |
| Multivariable test 2c | Model 3 | Model 4 | ||
| Her2 negative and Ki-67 negative | 1 (reference) | 1 (reference) | ||
| Her2 negative and Ki-67 positive | 0.13 (0.03–0.64) | 0.039 | 1.27 (0.65–2.49) | 0.601 |
| Her2 positive and Ki-67 negative | 0.07 (0.01–0.48) | 0.015 | 1.64 (0.57–4.74) | 0.706 |
| Her2 positive and Ki-67 positive | 0.06 (0.01–0.37) | 0.009 | 2.01 (0.80–5.00) | 0.263 |
Significant associations are shown in italics
pT stage pathological tumor stage, pN stage pathological node stage, Her2 human epidermal growth factor receptor 2, OR odds ratio, CI confidence interval
aPerformed using univariable logistic regression
bPerformed using multivariable logistic regression with adjustment for age, sex, tumor location, length, and differentiation grade
cpN stage was additionally adjusted for in Model 3, and pT stage in Model 4